오리지널 바다이야기 베스트 고래나오기 꽁머니로 시작한다 게시자: 바다이야기 5개월 전 7분 40초 조회수 32회
HAMBURG, GERMANY & TOKYO, JAPAN--( / ) April 23, 2020 -- Olympus Corporation (President: Yasuo Takeuchi) today announced the launch of EVIS X1, its most advanced endoscopy system to date. The new system is to improve outcomes from disorders of the stomach, colon, and oesophagus, as well as from bronchial diseases, by providing every endoscopist with innovative and proven tools. The launch of EVIS X1 further strengthens Olympus’ leadership in endoscopy and continued medical focus.
EVIS X1 supports accurate screening and confident diagnosis through introducing new and easy-to-use technologies to support how gastrointestinal disorders, such as colorectal cancer (CRC), or bronchial diseases are detected, characterized and treated. These include Extended Depth of Field (EDOF), Red Dichromatic Imaging (RDI), Texture and Color Enhancement Imaging (TXI) as well as the already known and proven Narrow Band Imaging (NBI). Being committed to innovation, Olympus is also already developing future technologies - in particular featuring artificial intelligence (AI).
“EVIS X1 is the latest innovation to build on our 100-year legacy of world-leading innovation and quality,” said Frank Drewalowski, Head of Endoscopic Solutions Division, Olympus Corporation. “We are proud that, with EVIS X1, we can support endoscopists around the world and help to elevate the standard of endoscopy across the board.”
Combining knowledge, experience and innovation in one endoscopic system
The key features of the EVIS X1 system include:
· Extended Depth of Field (EDOF): EDOF combines two images at different focal lengths into one perfect image to help aid diagnosis and confident decision-making. It delivers observational excellence through continuous broad focus and seamless magnification. At the same time, the established Dual Focus function provides high magnification, which can be activated by the push of a button. This improved visibility and continuously sharp image has been developed to reduce the necessity for focal adjustments and could improve efficiency and decrease the oversight rate.
· Red Dichromatic Imaging (RDI): Gastrointestinal bleeding is a serious challenge, potentially involving considerable mortality and management costs. RDI enhances the visibility of deep blood vessels and GI bleeding sources, thereby helping to identify blood vessels that could require immediate treatment. It utilizes green, amber and red wavelengths to visualize deep blood vessels. Easier identification of bleeding spots makes hemostasis quicker and easier whilst potentially improving the efficiency of any corresponding treatment. This minimally invasive technology could also help reduce physician stress during endoscopic therapy.
· Texture and Color Enhancement Imaging (TXI): TXI supports better visibility of potential and extant lesions (such as areas of inflammation, flat or depressed lesions, or even tiny precursor lesions) through enhancing texture, brightness and color to define subtle tissue differences more clearly. With its advanced imaging technology, TXI holds the potential to reinvent white light in endoscopy. By supporting better visibility of potential and extant lesions, TXI aims to contribute to higher detection rates and improve qualitative diagnosis.
· Narrow Band Imaging (NBI): NBI is an already known, powerful and proven optical technology that allows for a high-confidence optical diagnosis through the creation of a strong contrast between vessels and surrounding mucosa. It utilizes specific blue and green wavelengths. NBI not only supports earlier detection of any lesions but also provides a more detailed, higher-contrasted visualization and thus improves qualitative diagnosis.
Being ready for the future
The next upcoming feature of the EVIS X1 system will be AI. Olympus is developing innovative new ways to integrate breakthroughs in deep learning into the world of image detection, characterization, staging, and treatment.
Beyond introducing new features, EVIS X1 also provides newly established cross-compatibility between two formerly separate systems: EVIS LUCERA ELITE and EVIS EXERA III. This means that Olympus’ existing range of products can be combined to provide an extended portfolio of endoscopes for special procedures - expanding the possibilities for endoscopists.
Focusing on colorectal cancer prevention
Especially by helping to facilitate screening and early detection of abnormalities in the gastrointestinal tract, EVIS X1 could play a major role in the prevention of colorectal cancer (CRC). In 2018, there were 1.80 million cases of colorectal cancer and 862,000 patient deaths worldwide.[i] It is also expected that the global burden of CRC will increase substantially by 2030.[ii] For every 1% increase in adenoma detection rate (ADR), there is a 3% decrease in CRC risk.[iii]
“Early detection and diagnosis is critical for CRC prevention,” said Prof. Michal F. Kaminski, Professor at the National Research Institute of Oncology in Warsaw. “EVIS X1 is intuitive and gives endoscopists a range of innovative and proven tools to carry out minimally invasive, precise and effective procedures - enabling them to make truly-informed diagnostic and treatment decisions in the best interest of their patients. Among the new technologies especially TXI looks promising. It seems to provide more information to the endoscopist while maintaining a close to white light appearance. This will make it very easy to adapt to it.”
Reaffirming leadership in endoscopy
EVIS X1 is not only anticipated to serve healthcare professionals, hospital management and patients around the world but also follows Olympus’ implementation of its strategy. “Our purpose is to make people’s lives healthier, safer and more fulfilling,” said Takaharu Yamada, Vice President, GI Endoscopy Business, Global, Olympus Corporation. “This launch also strengthens our global leadership in endoscopy and follows our focus of the corporate portfolio centering on the medical business.”
EVIS X1 is initially being launched in EMEA (Europe, Middle East & Africa), Australia, India and Hong Kong. It is manufactured by Olympus Medical Systems Corporation. The company and product names specified in this release are the trademarks or registered trademarks of Olympus.
About Olympus
Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products. For more than 100 years, Olympus has focused on making people’s lives healthier, safer, and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, ensuring public safety, and capturing images of the world.
Olympus Endoscopic Solutions uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ endoscopic portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as systems integration solutions and medical services.
For more information, please visit:
About EVIS X1
For further information about EVIS X1, please visit:
For regular updates and engagement, please follow us on social media at:
· Twitter:
· LinkedIn:
References
[i] WHO Cancer Factsheet. Available: Accessed February 2020.
[ii] Global patterns and trends in colorectal cancer incidence and mortality. Accessed February 2020.
[iii] Corley DA, Jensen CD, Marks AR, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. N Engl J Med. 2014;370:1298-1306. Available at: Accessed February 2020.
View source version on businesswire.com:EVIS X1 CV-1500 front
TOKYO--( / ) January 29, 2018 -- TOKYO--(Electronic Devices & Storage Corporation today 확대콘돔 announced the development of “TaRF10,” a next generation TarfSOITM (Toshiba 예스젤 advanced RF 릴게임 야한란제리 TOKYO--(릴게임 process optimized TOKYO--(low-noise amplifiers (LNAs) in smartphone applications.
In recent years, the increasing Inof mobile data 릴게임 글로벌프로텍션플레져플러스 communication has expanded use of RF switches and filters in the analog 릴게임 성인용품후기 front end of mobile devices. The resulting increase in signal loss between 패들 antenna and receiver circuit has degraded receiver sensitivity, and focused attention on LNAs with a low noise 엠빅스에스 figure[2] (NF) as a means to compensate for signal loss and improve the integrity of the received signal.
Toshiba Electronic Devices Toshiba 릴게임바다이야기 Storage Toshibaused its new TaRF10 process to develop a prototype LNA with 릴게임 번개팅 an outstanding noise figure 시알리스제네릭 of 0.72dB and a gain[3] of 16.9dB at a frequency of 1.8GHz.
Mobiledevices use many RF switches and LNAs in the receiver circuit, generating 비뇨기과전문병원 a need 릴게임 바다이야기환전 to reduce circuit size in order 릴게임 비아그라100 to reduce board area utilization. Current LNAs 바람피는남편 typically use silicon-germanium-carbon (SiGe:C) 아내외도 bipolar transistors, and it Mobilebeen difficult to integrate LNAs and RF switches fabricated with different Mobileon the same chip.
The new 릴게임 남성천연식품 TaRF10 process can integrate LNAs, control circuits and RF switches on a single chip, as it is highly compatible with the TaRF8 and TaRF9 processes for RF switches, which secure outstanding RF characteristics. TaRF9 무료야동 realizes lower insertion loss and signal distortion than TaRF8. Toshiba Electronic Devices & Storage now plans to bring to market Thewith integrated RF switches.
Toshiba Electronic Devices & Storage has developed ToshibaICs utilizing its subsidiary, Japan Semiconductor Corporation 모아따 to 노블타운 apply the latest SOI-CMOS technology, and by handling all aspects of the production 릴게임 휴지킹 flow, from RF process technology development to the 릴게임 야동판 design and manufacturing, Toshiba 물사냥 a Toshiba릴게임 비아그라100mg products launch.
To meet next-generation market Tofor 5G smartphones, the company will continue to further Tothe characteristics of 누나넷 the TarfSOITM process and develop RF ICs 릴게임 밤에남자 with cutting-edge To
[2] Noise figure: the ratio [2]릴게임 더블업카지노 signal-to-noise ratio at the output to that mtHoCyV [2]the input. The 강원랜드카지노 lower the 에볼루션카지노 noise figure, the lower the amplifier self-noise is and therefore 비아그라지속시간 the better.
[3] Gain: 릴게임 카가얀호텔카지노 the ratio of the output power of an amplifier 온라인릴게임 [3]its 릴게임 팔팔정지속시간 input power 발기부전원인 릴게임 발기부전원인 in dB
* Company names, * 릴게임 names, *service names mentioned herein may 릴게임 자위중독증세 be trademarks of their respective companies.
Customer 비아그라처방 Customer 릴게임
Small Signal Small Small릴게임 하얏트호텔카지노 & Small 합법카지노 릴게임 합법카지노 Department
Tel: Tel: 캄보디아카지노 릴게임 캄보디아카지노
*Information in this document, including product prices and specifications, content of services and 릴게임 힐튼호텔카지노 contact information, is current 성욕감퇴 on *Information릴게임 조루수술비 date of the announcement but is subject 릴게임 네노마 to 벨루가카지노 change *Informationprior notice.
About Toshiba Electronic 릴게임 화일약품 Devices 릴게임 베트남호텔카지노 & 릴게임 베네시안카지노 Storage About 조루증치료제
Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with Toshibawisdom of experience. Since being spun off 릴게임 스테미너음식 from Toshiba Corporation in July 야관문주 2017, we have taken our place among the leading general devices companies, and offer our customers and Toshibapartners outstanding solutions in discrete semiconductors, system LSIs and HDD.
Our 19,000 employees around the world share Ourdetermination to maximize the value of our products, and emphasize close collaboration with customers to promote co-creation of value and new markets. We look Ourto building on annual sales now surpassing 700-billion 릴게임 스포츠토토배당률보기프로토 yen (US$6 billion) and to contributing to 릴게임 당신의스포츠와함께합니다.스포츠토토 a better future for people everywhere.
Find Findmore 릴게임 라이브스코어어플 about us 비뇨기과전문병원 Find
View source VIGRX version 라이브스코어맨 View 라이브스코어알바 businesswire.com:Korea Newswire distributes your 릴게임 흘사기 news across every media channels through the industry’s largest 릴게임 스코어보드 press release distribution network
전화번호 : 
영업시간 : 
홈페이지 : 
위치정보 : 